Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News12 hours agoTeenage girl dies in hit-and-run, police hunt for ute
-
Noosa News7 hours agoArnie the dog found dead in stolen ute after week of searching
-
Noosa News14 hours agoTeenage girl killed in alleged hit-and-run at Margate north of Brisbane
-
Noosa News7 hours ago‘Beyond devastated’ Brisbane family learn missing German shepherd Arnie found dead in back of stolen car